Matrix metalloproteinases (MMPs) are a family of zinc endopeptidases that
cleave nearly all components of the extracellular matrix as well as many other
soluble and cell-associated proteins. MMPs have been implicated in normal
physiological processes, including development, and in the acquisition and
progression of the malignant phenotype. Disappointing results from a series of
clinical trials testing small molecule, broad spectrum MMP inhibitors as cancer
therapeutics led to a re-evaluation of how MMPs function in the tumor
microenvironment, and ongoing research continues to reveal that these proteins
play complex roles in cancer development and progression. It is now clear that
effective targeting of MMPs for therapeutic benefit will require selective
inhibition of specific MMPs. Here, we provide an overview of the MMP family and
its biological regulators, the tissue inhibitors of metalloproteinases (TIMPs).
We then summarize recent research from model systems that elucidate how specific
MMPs drive the malignant phenotype of breast cancer cells, including acquisition
of cancer stem cell features and induction of the epithelial-mesenchymal
transition, and we also outline clinical studies that implicate specific MMPs in
breast cancer outcomes. We conclude by discussing ongoing strategies for
development of inhibitors with therapeutic potential that are capable of
selectively targeting the MMPs most responsible for tumor promotion, with
special consideration of the potential of biologics including antibodies and
engineered proteins based on the TIMP scaffold.